This inventor holds 2 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Eli Lilly and Company. Active years: 2024-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024-2026
Title: The Innovations of Jeffrey S. Riesmeyer
Introduction
Jeffrey S. Riesmeyer is an accomplished inventor based in Indianapolis, IN. He has made significant contributions to the field of medicine, particularly in the treatment of type 2 diabetes mellitus (T2DM). His innovative work focuses on reducing cardiovascular risks associated with this condition.
Latest Patents
Riesmeyer holds a patent for "Therapeutic uses of dulaglutide." This invention relates to methods for reducing the risk of major adverse cardiovascular events in T2DM patients who have multiple cardiovascular risk factors. The patent emphasizes the administration of the glucagon-like peptide-1 (GLP-1) receptor agonist dulaglutide to achieve these health benefits. He has 1 patent to his name.
Career Highlights
Riesmeyer is associated with Eli Lilly and Company, a leading pharmaceutical firm known for its commitment to innovation in healthcare. His work at Eli Lilly has allowed him to contribute to groundbreaking research and development in diabetes treatment.
Collaborations
One of his notable collaborators is David Bradley Woodward. Together, they have worked on advancing therapeutic methods that can significantly impact patient care.
Conclusion
Jeffrey S. Riesmeyer's contributions to the field of diabetes treatment through his innovative patent demonstrate his commitment to improving patient outcomes. His work continues to influence the medical community and offers hope for better management of cardiovascular risks in T2DM patients.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile